Figure 3.

Clinical and paraclinical measurements in patients with polymyalgia rheumatica at baseline (black bars) and after (white bars) 14 days of treatment with etanercept or placebo. C-reactive protein (CRP), patients' ability to elevate the arms (E, 3 to 0: 3 = no elevation possible; 2 = elevation possible below shoulder height; 1 = elevation possible above shoulder height; 0 = full elevation possible), the physician's global assessment (visual analog score, VAS), and erythrocyte sedimentation rate (ESR).